S
Steven J. Rosansky
Researcher at University of South Carolina
Publications - 48
Citations - 2390
Steven J. Rosansky is an academic researcher from University of South Carolina. The author has contributed to research in topics: Dialysis & Renal function. The author has an hindex of 24, co-authored 48 publications receiving 2188 citations. Previous affiliations of Steven J. Rosansky include United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease
L. Darryl Quarles,Donald J. Sherrard,Stephen Adler,Steven J. Rosansky,Laura C. McCary,Wei Liu,Stewart A. Turner,David A. Bushinsky +7 more
TL;DR: The calcimimetic AMG 073 at doses up to 100 mg for 18 wk provided a safe and effective means to attain significant reductions in PTH and calcium x phosphorus levels in ESRD patients.
Journal ArticleDOI
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
Daniel W. Coyne,Muralidhar Acharya,Ping Qiu,Hanna E. Abboud,Daniel Batlle,Steven J. Rosansky,Stephen Z. Fadem,Barton S. Levine,Laura A. Williams,Dennis L. Andress,Stuart M. Sprague +10 more
TL;DR: Paricalcitol capsule was well tolerated and effectively decreased iPTH levels with minimal or no impact on calcium levels, phosphorus balance, and kidney function in patients with stages 3 and 4 CKD.
Journal ArticleDOI
Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Christopher T. Chan,Peter J. Blankestijn,Laura M. Dember,Maurizio Gallieni,David Harris,Charmaine E. Lok,Rajnish Mehrotra,Paul E. Stevens,Angela Yee-Moon Wang,Michael Cheung,David C. Wheeler,Wolfgang C. Winkelmayer,Carol A. Pollock,Ali K. Abu-Alfa,Joanne M. Bargman,Anthony J. Bleyer,Edwina A. Brown,Andrew Davenport,Simon J. Davies,Frederic O. Finkelstein,Jennifer E. Flythe,Eric Goffin,Thomas A. Golper,Rafael Gomez,Takayuki Hamano,Manfred Hecking,Olof Heimbürger,Barnaby Hole,Daljit Hothi,T. Alp Ikizler,Yoshitaka Isaka,Kunitoshi Iseki,Vivekanand Jha,Hideki Kawanishi,Peter G. Kerr,Paul Komenda,Csaba P. Kovesdy,Ed Lacson,Maurice Laville,Jung Pyo Lee,Edgar V. Lerma,Nathan W. Levin,Monika Lichodziejewska-Niemierko,Adrian Liew,Elizabeth Lindley,Robert S. Lockridge,Magdalena Madero,Ziad A. Massy,Linda M. McCann,Klemens B. Meyer,Rachael L. Morton,Annie Claire Nadeau-Fredette,Hirokazu Okada,José Pérez,Jeff Perl,Kevan R. Polkinghorne,Miguel C. Riella,Bruce M. Robinson,Michael V. Rocco,Steven J. Rosansky,Joris I. Rotmans,María Fernanda Slon Roblero,Navdeep Tangri,Marcello Tonelli,Allison Tong,Yusuke Tsukamoto,Kriang Tungsanga,Tushar J. Vachharajani,Ismay van Loon,Suzanne Watnick,Daniel E. Weiner,Martin Wilkie,Elena Zakharova +72 more
TL;DR: The need to move away from a "one-size-fits-all" approach to dialysis and provide more individualized care that incorporates patient goals and preferences while still maintaining best practices for quality and safety is represented during the KDIGO conference.
Journal ArticleDOI
Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
TL;DR: Among patients with euvolemic or hypervolemic hyponatremia, 4-day intravenous infusion of conivaptan 40 mg/day significantly increased serum [Na+] and was well tolerated.
Journal ArticleDOI
Initiation of dialysis at higher GFRs: is the apparent rising tide of early dialysis harmful or helpful?
TL;DR: US dialysis data, national guidelines, and publications relevant to the early start phenomenon are examined, finding that comorbidities present at the time of dialysis initiation do not appear to be a major driving force for early start patients.